世界最先端の研究で医学の発展に寄与

2014年

2014年 業績・論文

Takamatsu A, Abe Y, Suehiro Y, Choi I, Toyoda K, Shiratsuchi M, Uike N.

Successful treatment with allogeneic hematopoietic stem cell transplant in a mature B-cell leukemia with MYC and BCL2 translocation.

Leuk Lymphoma. 55(7):1663-4. 2014.

 

Toyoda K, Abe Y, Tsuda M, Haji S, Choi I, Suehiro Y, Kiyasu J, Ohshima K, Uike N.

[Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma].

Rinsho Ketsueki. 55(7):815-9. 2014.

 

Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, Abe Y, Hayashi T, Sawamoto H, Kaneko K, Shimokawa M, Nakagawa M.

Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era.

Int J Hematol. 100(4):386-92. 2014.

 

Hayashi H, Takamune N, Nirasawa T, Aoki M, Morishita Y, Das D, Koh Y, Ghosh AK, Misumi S, Mitsuya H.

Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

Proc Natl Acad Sci U S A. 111(33):12234-9. 2014.

 

Miyazaki Y, Taguchi K, Sou K, Watanabe H, Ishima Y, Miyakawa T, Mitsuya H, Fukagawa M, Otagiri M, Maruyama T.

Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia.

Mol Pharm. 11: 4238-48. 2014.

 

Ghosh AK, Schiltz GE, Rusere LN, Osswald HL, Walters DE, Amano M, Mitsuya H.

Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.

Org Biomol Chem. 12(35):6842-54. 2014.

 

Michailidis E, Huber AD, Ryan EM, Ong YT, Leslie MD, Matzek KB, Singh K, Marchand B, Hagedorn AN, Kirby KA, Rohan LC, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

J Biol Chem. 289(35):24533-48. 2014.

 

Yedidi RS, Garimella H, Aoki M, Aoki-Ogata H, Desai DV, Chang SB, Davis DA, Fyvie WS, Kaufman JD, Smith DW, Das D, Wingfield PT, Maeda K, Ghosh AK, Mitsuya H.

A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.

Antimicrob Agents Chemother. 58(7):3679-88. 2014.

 

Muftuoglu Y, Sohl CD, Mislak AC, Mitsuya H, Sarafianos SG, Anderson KS.

Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.

Antiviral Res. 106:1-4. 2014.

 

Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.

Eur J Haematol. 92(6):471-7. 2014.

 

Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H.

EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.

J Invest Dermatol. 134(4):1158-61. 2014.

 

Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H.

Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.

Antivir Ther. 19(2):179-89. 2014.

 

Nederer HA, Laydon DJ, Melamed A, Elemans M, Asquith B, Matsuoka M, Bangham CR.

HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP.

Virology J. 11: 172. 2014.

 

Lavorgna A, Matsuoka M, Harhaj EW.

A critical role for IL-17RB signaling in HTLV-1 Tax-induced NF-κB activation and T-cell transformation.

PLoS Pathog. 10: e1004418. 2014.

 

Cook LB, Melamed A, Niederer H, Valganon M, Laydon D, Foroni L, Taylor GP, Matsuoka M, Bangham CR.

The role of HTLV-1 clonality, proviral structure and genomic integration site in adult T cell leukemia/lymphoma.

Blood. 123: 3925-31. 2014.

 

Zhao, T, Satou Y, Matsuoka M.

Development of T cell lymphoma in HTLV-1 bZIP factor and Tax double transgenic mice.

Arch Virol. 159: 1849-56. 2014.

 

Azuma Y, Kükenshöner T, Ma G, Yasunaga JI, Imanishi M, Arndt KM, Matsuoka M, Futaki S.

Controlling leucine-zipper partner recognition in cells through modifications of a-g interactions.

Chem Commun. 50: 6364-7. 2014.

 

Tanaka-Nakanishi A, Yasunaga J-I, Takai K, Matsuoka M.

HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization.

Cancer Res. 74:188-200. 2014.

 

Zhang W, Parniak MA, Mitsuya H, Sarafianos SG, Graebing PW, Rohan LC. Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention.

Drug Dev Ind Pharm. 40(8):1101-11. 2014.

お気軽にお問い合わせください TEL 096-373-5156 受付時間 9:00 - 18:00 [ 土・日・祝日除く ]

  • Facebook
  • Hatena
  • twitter
  • Google+
PAGETOP